NO20091736L - IL-17-reseptor A-antigenbindende proteiner - Google Patents

IL-17-reseptor A-antigenbindende proteiner

Info

Publication number
NO20091736L
NO20091736L NO20091736A NO20091736A NO20091736L NO 20091736 L NO20091736 L NO 20091736L NO 20091736 A NO20091736 A NO 20091736A NO 20091736 A NO20091736 A NO 20091736A NO 20091736 L NO20091736 L NO 20091736L
Authority
NO
Norway
Prior art keywords
receptor
antigen
binding proteins
antibodies
i7ra
Prior art date
Application number
NO20091736A
Other languages
English (en)
Other versions
NO344867B1 (no
Inventor
Joel Tocker
Jacques Peschon
David Fitzpatrick
James F Smothers
Christopher Mehlin
Ai Ching Lim
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20091736L publication Critical patent/NO20091736L/no
Publication of NO344867B1 publication Critical patent/NO344867B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse gjelder IL-17-reseptor A (IL- I 7RA eller IL- I 7R)-antigenbindende proteiner, for eksempel antistoffer, polynukleotidsekvenser som koder for de antigenbindende proteinene, og preparater og fremgangsmåter for diagnose og behandling av sykdommer som formidles ved IL- 17reseptor A-aktivering via én eller flere IL-17-ligander. Foreliggende oppfinnelse gjelder identifisering av nøytraliserende determinanter i IL- 17-reseptor A (IL17RA eller IL-17R) og antistoffer som bindes til disse. Aspekter av oppfinnelsen omfatter også antistoffer som konkurrerer om binding med de IL- I 7RAnøytraliserende antistoffene som beskrives heri.
NO20091736A 2006-10-02 2009-04-30 Isolert antistoff eller fragment derav som binder IL-17 reseptor A, farmasøytisk sammensetning derav, polynukleotid som koder for antistoffet, et plasmidet som inneholder polynukleotidet, en celle som omfatter plasmidet, en fremgangsmåte for fremstilling av antistoffet, og dets anvendelse ved behandling av en sykdom eller patologisk tilstand assosiert med IL-17 reseptor A aktivering. NO344867B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82788206P 2006-10-02 2006-10-02
US87307206P 2006-12-05 2006-12-05
US96989507P 2007-09-04 2007-09-04
PCT/US2007/021174 WO2008054603A2 (en) 2006-10-02 2007-10-01 Il-17 receptor a antigen binding proteins

Publications (2)

Publication Number Publication Date
NO20091736L true NO20091736L (no) 2009-06-30
NO344867B1 NO344867B1 (no) 2020-06-08

Family

ID=39344834

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20091736A NO344867B1 (no) 2006-10-02 2009-04-30 Isolert antistoff eller fragment derav som binder IL-17 reseptor A, farmasøytisk sammensetning derav, polynukleotid som koder for antistoffet, et plasmidet som inneholder polynukleotidet, en celle som omfatter plasmidet, en fremgangsmåte for fremstilling av antistoffet, og dets anvendelse ved behandling av en sykdom eller patologisk tilstand assosiert med IL-17 reseptor A aktivering.
NO2020036C NO2020036I1 (no) 2006-10-02 2020-10-28 Isolert antistoff eller fragment derav omfattende lett kjede og tung kjede CDR-sekvenser ifølge NO344867 krav 1 (SEQ ID NO: 224, 225, 226 og 146, 147, 148), der antistoffet eller fragmentet derav binder human IL-17 reseptor A; spesielt et antistoff omfattende lett kjede og tung kjede variable domenesekvenser ifølge NO344867 krav 2 (SEQ ID NO: 40 and 14); slik som et IgG2 antistoff omfattende lett og tung kjede variable domenesekvenser ifølge NO344867 krav 4 (SEQ ID NO: 40 and 14); og spesielt brodalumab; og dets derivater dekket av NO344867.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2020036C NO2020036I1 (no) 2006-10-02 2020-10-28 Isolert antistoff eller fragment derav omfattende lett kjede og tung kjede CDR-sekvenser ifølge NO344867 krav 1 (SEQ ID NO: 224, 225, 226 og 146, 147, 148), der antistoffet eller fragmentet derav binder human IL-17 reseptor A; spesielt et antistoff omfattende lett kjede og tung kjede variable domenesekvenser ifølge NO344867 krav 2 (SEQ ID NO: 40 and 14); slik som et IgG2 antistoff omfattende lett og tung kjede variable domenesekvenser ifølge NO344867 krav 4 (SEQ ID NO: 40 and 14); og spesielt brodalumab; og dets derivater dekket av NO344867.

Country Status (30)

Country Link
US (14) US7767206B2 (no)
EP (4) EP2518085B1 (no)
JP (1) JP5013383B2 (no)
KR (2) KR101240903B1 (no)
CN (1) CN103214576B (no)
AR (1) AR063090A1 (no)
AU (2) AU2007314519C1 (no)
BR (1) BRPI0719762B8 (no)
CA (1) CA2663537C (no)
CL (1) CL2007002800A1 (no)
CR (1) CR10760A (no)
CY (5) CY1116291T1 (no)
DK (4) DK2487188T3 (no)
EA (1) EA019397B1 (no)
ES (4) ES2533352T3 (no)
HU (4) HUE057611T2 (no)
IL (3) IL197636B (no)
LT (4) LT2487188T (no)
LU (1) LUC00056I2 (no)
MX (1) MX2009003511A (no)
MY (1) MY187263A (no)
NL (1) NL300919I2 (no)
NO (2) NO344867B1 (no)
NZ (1) NZ575631A (no)
PE (2) PE20120832A1 (no)
PL (4) PL3165539T3 (no)
PT (4) PT2518085T (no)
SI (4) SI2076541T1 (no)
TW (1) TWI396694B (no)
WO (1) WO2008054603A2 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2056838B1 (en) * 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CA2687720A1 (en) * 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
US20100256600A1 (en) * 2009-04-04 2010-10-07 Ferrera David A Neurovascular otw pta balloon catheter and delivery system
KR101240904B1 (ko) * 2008-02-21 2013-03-11 키린-암젠 인코포레이티드 Ｉｌ-１７ｒａ-ｉｌ-１７ｒｂ 길항제 및 그의 용도
JP2012504953A (ja) * 2008-10-07 2012-03-01 ノビミューン エスアー Ｉｌ−１７媒介性トランスフェクション法
WO2010062858A1 (en) * 2008-11-26 2010-06-03 Allergan, Inc. Il-17 antibody inhibitor for treating dry eye
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
TW201117824A (en) * 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
AR078751A1 (es) 2009-10-23 2011-11-30 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
JP5743234B2 (ja) 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド 抗体製剤及び治療レジメン
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
CA2791951C (en) 2010-05-20 2019-05-14 Ablynx Nv Biological materials related to her3
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
RU2582937C2 (ru) 2010-11-05 2016-04-27 Новартис Аг Способы лечения ревматоидного артрита с применением антагонистов il-17
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2699293B8 (en) 2011-04-20 2022-07-20 Amgen Inc. Autoinjector apparatus
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP6165727B2 (ja) 2011-07-19 2017-07-19 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 新規ｉｌ−１７ｒ−ｅｃｄ変異体
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2948178A4 (en) 2013-01-25 2016-07-20 Thymon Llc COMPOSITIONS FOR THE SELECTIVE REDUCTION OF CIRCULATING BIOACTIVE SOLUBLE TNF AND METHODS OF TREATING A TNF MEDIATION DISEASE
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
KR102074421B1 (ko) * 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
BR112016018980A2 (pt) 2014-02-21 2017-10-10 Genentech Inc método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
SG11201607881SA (en) 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
EP3185902B1 (en) * 2014-08-26 2020-07-29 Amgen K-A, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
DK3191120T3 (da) 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
GB201500461D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
JP2018521047A (ja) 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
WO2018013939A1 (en) * 2016-07-14 2018-01-18 Scholar Rock, Inc. Tgfb antibodies, methods, and uses
WO2018067198A1 (en) * 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
US20200131518A1 (en) 2017-03-14 2020-04-30 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
EP3638697A4 (en) * 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
CA3080665A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17) antagonists
CA3084486A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
TW202000233A (zh) 2018-02-22 2020-01-01 學校法人東海大學 Il-17a活性抑制劑及其用途
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CA3097369A1 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
WO2021048359A1 (en) * 2019-09-11 2021-03-18 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
TW202126330A (zh) 2019-09-25 2021-07-16 國立大學法人東京大學 全身性硬化症治療用醫藥組合物
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4405379A1 (en) * 2021-09-24 2024-07-31 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197525A (en) * 1961-08-07 1965-07-27 Union Oil Co Clathration process
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
DK0502956T3 (da) 1989-11-29 1997-10-20 Amgen Boulder Inc Fremstilling af en rekombinant human interleukin-1-inhibitor.
JPH0578396A (ja) 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd ヒト腫瘍壊死因子結合蛋白
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DE4013159A1 (de) 1990-04-25 1991-10-31 Bosch Gmbh Robert Gehaeuseblock fuer ein hydraulisches bremssystem
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
AU1235692A (en) 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE69230862T2 (de) 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
DK0639079T3 (da) 1992-04-30 2000-06-13 Amgen Inc Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
DE4219626A1 (de) 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
ATE257389T1 (de) 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
EP0701563A4 (en) 1993-03-08 1997-07-02 Univ Pittsburgh GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL
WO1994021275A1 (fr) 1993-03-19 1994-09-29 Vacsyn S.A. Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
ATE279517T1 (de) 1995-03-23 2004-10-15 Immunex Corp Il-17 receptor
DK0839196T3 (da) 1995-07-19 2005-09-12 Inst Genetics Llc Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
NZ503548A (en) 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
WO1998023284A1 (en) 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
EP1015872B1 (en) 1996-12-12 2005-03-02 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2324648C (en) 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6144598A (en) * 1999-07-06 2000-11-07 Micron Technology, Inc. Method and apparatus for efficiently testing rambus memory devices
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
AR028256A1 (es) 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1326626B1 (en) 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003280017A1 (en) 2002-06-27 2004-01-19 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003258169A1 (en) * 2002-08-09 2004-02-25 Zehra Rowjee Pharmacological treatment of psoriasis
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1651190B1 (en) 2003-08-05 2012-09-19 3M Innovative Properties Company Formulations containing an immune response modifier
US8119340B2 (en) * 2003-10-08 2012-02-21 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
JPWO2005063291A1 (ja) 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
CN102702359A (zh) * 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US20090007475A1 (en) 2004-12-16 2009-01-08 Pollock Linda R Tool and Method for Organizing a Vertically Stacked Pile of Items
BRPI0608210A2 (pt) 2005-02-14 2010-11-09 Wyeth Corp métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
WO2007047738A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
PE20110803A1 (es) 2005-11-01 2011-11-07 Wyeth Corp Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
CA2687720A1 (en) 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
JP2010536786A (ja) 2007-08-17 2010-12-02 アムジエン・インコーポレーテツド ポリカチオンを用いた抗体およびｆｃ融合分子の製剤
KR101240904B1 (ko) 2008-02-21 2013-03-11 키린-암젠 인코포레이티드 Ｉｌ-１７ｒａ-ｉｌ-１７ｒｂ 길항제 및 그의 용도
AU2010303166A1 (en) 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP5743234B2 (ja) 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド 抗体製剤及び治療レジメン
EP3299390A1 (en) 2010-10-08 2018-03-28 Novartis AG Methods of treating psoriasis using il-17 antagonists
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
SG11201607881SA (en) 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
EP3185902B1 (en) 2014-08-26 2020-07-29 Amgen K-A, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
US20100292442A1 (en) 2010-11-18
JP5013383B2 (ja) 2012-08-29
LTPA2018003I1 (lt) 2018-02-12
PE20081625A1 (es) 2009-01-11
US20200362045A1 (en) 2020-11-19
PL2518085T3 (pl) 2017-08-31
KR20090088870A (ko) 2009-08-20
EP2518085A1 (en) 2012-10-31
WO2008054603A3 (en) 2008-09-25
US7786284B2 (en) 2010-08-31
CN103214576A (zh) 2013-07-24
US20080221307A1 (en) 2008-09-11
EP2076541B1 (en) 2015-02-18
LT3165539T (lt) 2022-04-11
ES2533352T3 (es) 2015-04-09
AR063090A1 (es) 2008-12-23
US11180564B2 (en) 2021-11-23
CA2663537C (en) 2015-02-24
DK2518085T3 (en) 2017-02-13
LUC00056I1 (no) 2017-12-20
PL2076541T3 (pl) 2015-07-31
LT2518085T (lt) 2017-05-10
AU2007314519A1 (en) 2008-05-08
PT2487188T (pt) 2017-05-04
KR20120098953A (ko) 2012-09-05
TW200821326A (en) 2008-05-16
PE20120832A1 (es) 2012-08-11
ES2616210T3 (es) 2017-06-09
US20200017591A1 (en) 2020-01-16
BRPI0719762A2 (pt) 2014-01-28
US8790648B2 (en) 2014-07-29
CL2007002800A1 (es) 2008-05-23
CY2018001I1 (el) 2018-09-05
EP2518085B1 (en) 2016-12-07
EP2487188B1 (en) 2017-03-08
DK3165539T3 (en) 2022-02-14
LT2487188T (lt) 2017-05-10
AU2010219370B2 (en) 2011-01-27
MY187263A (en) 2021-09-16
MX2009003511A (es) 2009-06-26
NZ575631A (en) 2012-04-27
PT3165539T (pt) 2022-03-18
DK2076541T3 (en) 2015-03-30
EP3165539A1 (en) 2017-05-10
HUE057611T2 (hu) 2022-05-28
CY1116291T1 (el) 2017-02-08
BRPI0719762B1 (pt) 2019-08-20
CY1118994T1 (el) 2018-01-10
CA2663537A1 (en) 2008-05-08
BRPI0719762B8 (pt) 2021-05-25
HUE032421T2 (en) 2017-09-28
AU2007314519B2 (en) 2012-08-16
CY2018001I2 (el) 2018-09-05
CY1125133T1 (el) 2023-06-09
JP2010505416A (ja) 2010-02-25
US20160251443A1 (en) 2016-09-01
NO344867B1 (no) 2020-06-08
US10208122B2 (en) 2019-02-19
SI2518085T1 (sl) 2017-05-31
HUE033216T2 (hu) 2017-11-28
PL2487188T3 (pl) 2017-09-29
US7767206B2 (en) 2010-08-03
NL300919I2 (nl) 2018-04-11
US20080219979A1 (en) 2008-09-11
CY1118845T1 (el) 2018-01-10
EP2487188A2 (en) 2012-08-15
US7833527B2 (en) 2010-11-16
IL197636B (en) 2018-02-28
US20100028345A1 (en) 2010-02-04
US9073999B2 (en) 2015-07-07
PT2076541E (pt) 2015-03-31
US9096673B2 (en) 2015-08-04
NO2020036I1 (no) 2020-10-28
US20080220479A1 (en) 2008-09-11
US20110081339A1 (en) 2011-04-07
WO2008054603A9 (en) 2008-07-03
IL228672A0 (en) 2013-12-31
CN103214576B (zh) 2015-06-03
SI2487188T1 (sl) 2017-07-31
IL251908A0 (en) 2017-06-29
DK2487188T3 (en) 2017-06-19
LUC00056I2 (no) 2018-02-21
EP2076541A2 (en) 2009-07-08
AU2007314519C1 (en) 2013-06-06
PL3165539T3 (pl) 2022-04-25
SI3165539T1 (sl) 2022-05-31
IL197636A0 (en) 2011-08-01
US20140356355A1 (en) 2014-12-04
ES2624921T3 (es) 2017-07-18
KR101240903B1 (ko) 2013-03-14
IL228672A (en) 2017-11-30
EA200900514A1 (ru) 2009-10-30
US20110008841A1 (en) 2011-01-13
HUS1800005I1 (hu) 2018-07-30
EP2487188A3 (en) 2012-10-31
AU2010219370A1 (en) 2010-09-30
EP3165539B1 (en) 2021-12-08
US20120251547A1 (en) 2012-10-04
US20110166331A1 (en) 2011-07-07
TWI396694B (zh) 2013-05-21
CR10760A (es) 2009-05-27
US8435518B2 (en) 2013-05-07
LTC2076541I2 (lt) 2018-09-10
WO2008054603A2 (en) 2008-05-08
AU2010219370C1 (en) 2013-05-23
ES2906774T3 (es) 2022-04-20
EA019397B1 (ru) 2014-03-31
US11858999B2 (en) 2024-01-02
US8545842B2 (en) 2013-10-01
US20090074758A1 (en) 2009-03-19
SI2076541T1 (sl) 2015-05-29
US7939070B2 (en) 2011-05-10
PT2518085T (pt) 2017-03-13

Similar Documents

Publication Publication Date Title
NO20091736L (no) IL-17-reseptor A-antigenbindende proteiner
NL301089I2 (nl) imlifidase
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2008054561A3 (en) Proteins, nucleic acids encoding the same and associated methods of use
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2010021697A3 (en) Antibodies to ccr2
WO2009083009A3 (en) Monoclonal antibodies against cd32b
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
NO20083793L (no) Antistoffer mot amyloid-beta peptid
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
WO2012069433A3 (en) Antigen binding proteins to oncostatin m (osm)
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
WO2010122135A3 (en) Use of mixed lineage like kinase polypeptides (mlkl polypeptides) in cancer therapy
WO2007068913A3 (en) SRCR-B Domain Containing Proteins
TH166366A (no)
WO2005092923A3 (en) Cytonectin and gene inhibitors thereof
UA97645C2 (ru) АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ РЕЦЕПТОР ИНТЕРЛЕЙКИНА-6 ЧЕЛОВЕКА (hIL-6R)

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN K-A, US

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ISOLERT ANTISTOFF ELLER FRAGMENT DERAV OMFATTENDE LETT KJEDE OG TUNG KJEDE CDR- SEKVENSER IFOELGE NO344867 KRAV 1 (SEQ ID NO: 224 225, 226 OG 146, 147, 148) DER ANTISTOFFET ELLER FRAGMENTET DERAV BINDER HUMAN IL-17 RESEPTOR A; SPESIELT ET ANTISTOFF OMFATTENDE LETT KJEDE OG TUNG KJEDE VARIABLE DOMENESEKVENSER IFOELGE NO344867 KRAV 2 (SEQ ID NO: 40 AND 14); SLIK SOM ET IGG2 ANTISTOFF OMFATTENDE LETT OG TUNG KJEDE VARIABLE DOMENESEKVENSER IFOELGE NO344867 KRAV 4 (SEQ ID NO: 40 AND 14); OG SPESIELT BRODALUMAB; OG DETS DERIVATER DEKKET AV NO344867.; REG. NO/DATE: EU/1/16/1155 20170814

Spc suppl protection certif: 2020036

Filing date: 20201028

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: BRODALUMAB; REG. NO/DATE: EU/1/16/1155 20170814

Spc suppl protection certif: 2020036

Filing date: 20201028

Extension date: 20320719